Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $74.99$49.00 | $4.90/mg | In stock | Jul 8 |
| vial | 5mg | $59.99$55.00 | $11.00/mg | Out of stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 11-01260229 | Feb 2026 | 99.8% | MZ Biolabs | — | Unverified | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. BPC-157 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Ascension Peptides sell BPC-157?
Yes — Ascension Peptides currently lists BPC-157 in 2 variants starting at $49.00 ($4.90/mg).
Is Ascension Peptides's BPC-157 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Ascension Peptides's BPC-157, with the most recent showing 99.8% purity. Ascension Peptides holds an overall trust grade of C (71/100) across all 11 COAs on file.
What is Ascension Peptides's trust grade for BPC-157?
Ascension Peptides has an overall Disclosed Labs trust grade of C (71/100), computed from 11 COAs across all peptides. The most recent BPC-157 COA was issued by MZ Biolabs.
Where is the cheapest BPC-157?
As of the latest data, Alpha Peptides offers BPC-157 at $1.82/mg — compare with Ascension Peptides's listing at $4.90/mg. See the full BPC-157 price comparison.
Is BPC-157 legal to buy?
BPC-157 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs